Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Fatma AboulnasrAndrew D Badley

Abstract

TNF-related apoptosis inducing ligand (TRAIL) expression by immune cells contributes to antitumor immunity. A naturally occurring splice variant of TRAIL, called TRAILshort, antagonizes TRAIL-dependent cell killing. It is unknown whether tumor cells express TRAILshort and if it impacts antitumor immunity. We used an unbiased informatics approach to identify TRAILshort expression in primary human cancers, and validated those results with IHC and ISH. TRAILshort-specific mAbs were used to determine the effect of TRAILshort on tumor cell sensitivity to TRAIL, and to immune effector cell dependent killing of autologous primary tumors. As many as 40% of primary human tumors express TRAILshort by both RNA sequencing and IHC analysis. By ISH, TRAILshort expression is present in tumor cells and not bystander cells. TRAILshort inhibition enhances cancer cell lines sensitivity to TRAIL-dependent killing both in vitro and in immunodeficient xenograft mouse models. Immune effector cells isolated from patients with B-cell malignancies killed more autologous tumor cells in the presence compared with the absence of TRAILshort antibody (P < 0.05). These results identify TRAILshort in primary human malignancies, and suggest that TRAILshort bloc...Continue Reading

References

Mar 4, 1998·European Journal of Immunology·I JeremiasK M Debatin
Jan 20, 1999·Molecular Pathology : MP·R J Sneath, D C Mangham
Apr 5, 2000·The Journal of Biological Chemistry·J L BodmerP Schneider
Apr 15, 2000·Cellular and Molecular Life Sciences : CMLS·A V Philips, T A Cooper
Mar 10, 2001·Nature·E S LanderUNKNOWN International Human Genome Sequencing Consortium
Dec 26, 2001·Nature Genetics·Barmak Modrek, Christopher Lee
Jan 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Erika CretneyMark J Smyth
Feb 23, 2002·Trends in Genetics : TIG·Malka Nissim-Rafinia, Batsheva Kerem
Jul 5, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Guillaume DorothéeFathia Mami-Chouaib
Jan 7, 2004·The Journal of Experimental Medicine·Brian P O'ConnorRandolph J Noelle
Sep 21, 2005·Cellular Immunology·Christian NielsenSøren T Lillevang
Oct 21, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nadeen ZerafaMark J Smyth
Dec 15, 2007·The Journal of Clinical Investigation·Niklas FinnbergWafik S El-Deiry
Jul 9, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Marion TravertThierry Guillaudeux
Sep 20, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Erik L BrincksKevin L Legge
Mar 4, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey WiezorekJonathan Graves
Aug 24, 2011·The Journal of Biological Chemistry·David J SchneppleAndrew D Badley
Dec 6, 2011·Immunology Letters·Xavier FrigolaEugene D Kwon
Sep 28, 2013·Nature Genetics·UNKNOWN Cancer Genome Atlas Research NetworkJoshua M Stuart
Mar 5, 2016·Cell Death and Differentiation·D de MiguelL Martinez-Lostao
Mar 11, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric SanchezJames R Berenson
Apr 16, 2016·Nature Reviews. Cancer·Suzanne L TopalianDrew M Pardoll
Jun 4, 2016·Advances in Experimental Medicine and Biology·Rafael Bejar
May 20, 2017·Cancer Immunology Research·Jun ZhouF Stephen Hodi
May 26, 2017·Nature Reviews. Cancer·Silvia von KarstedtHenning Walczak
Dec 22, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Zilin NieAndrew D Badley
Dec 22, 2017·Signal Transduction and Targeted Therapy·Xiao YangChunsheng Li
Jan 11, 2018·British Journal of Cancer·Russell W JenkinsKeith T Flaherty
Jun 1, 2019·AIDS·Ana C PaimAndrew D Badley
Jun 14, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sekar NatesampillaiAndrew D Badley

❮ Previous
Next ❯

Citations

Aug 28, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Diego de Miguel, Julian Pardo
Apr 2, 2021·Frontiers in Molecular Biosciences·Martin SnajdaufZuzana Strizova

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

The Journal of Immunology : Official Journal of the American Association of Immunologists
Sekar NatesampillaiAndrew D Badley
The Journal of Immunology : Official Journal of the American Association of Immunologists
Zilin NieAndrew D Badley
Critical Reviews in Immunology
Fatma AboulnasrAndrew D Badley
© 2021 Meta ULC. All rights reserved